For help on how to get the results you want, see our search tips.
1645 results
Medicine
European public assessment reports (EPAR) Remove European public assessment reports (EPAR) filter
Categories
Human Remove Human filter
-
List item
Human medicine European public assessment report (EPAR): Imatinib Actavis (updated)
imatinib, Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Myelodysplastic-Myeloproliferative Diseases; Hypereosinophilic Syndrome; Dermatofibrosarcoma
Date of authorisation: 17/04/2013,
, Revision: 13, Withdrawn, Last updated: 05/07/2022
-
List item
Human medicine European public assessment report (EPAR): Fycompa (updated)
perampanel, Epilepsies, Partial
Date of authorisation: 23/07/2012, Revision: 27, Authorised, Last updated: 05/07/2022 -
List item
Human medicine European public assessment report (EPAR): Advate (updated)
octocog alfa, Hemophilia A
Date of authorisation: 02/03/2004, Revision: 31, Authorised, Last updated: 05/07/2022 -
List item
Human medicine European public assessment report (EPAR): Mysimba (updated)
bupropion hydrochloride, naltrexone hydrochloride, Obesity; Overweight
Date of authorisation: 26/03/2015,
, Revision: 22, Authorised, Last updated: 05/07/2022
-
List item
Human medicine European public assessment report (EPAR): Vizarsin (updated)
sildenafil, Erectile Dysfunction
Date of authorisation: 21/09/2009,, Revision: 18, Authorised, Last updated: 04/07/2022
-
List item
Human medicine European public assessment report (EPAR): Mysildecard (updated)
sildenafil citrate, Hypertension, Pulmonary
Date of authorisation: 15/09/2016,, Revision: 6, Authorised, Last updated: 04/07/2022
-
List item
Human medicine European public assessment report (EPAR): Benlysta (updated)
belimumab, Lupus Erythematosus, Systemic
Date of authorisation: 13/07/2011,, Revision: 28, Authorised, Last updated: 04/07/2022
-
List item
Human medicine European public assessment report (EPAR): Sildenafil Teva (updated)
sildenafil, Erectile Dysfunction
Date of authorisation: 30/11/2009,, Revision: 17, Authorised, Last updated: 04/07/2022
-
List item
Human medicine European public assessment report (EPAR): Filsuvez (updated)
dry extract from birch bark (DER 5-10 : 1), extraction solvent n-heptane 95% (w/w), Epidermolysis Bullosa Dystrophica; Epidermolysis Bullosa, Junctional
Date of authorisation: 21/06/2022,
, Authorised, Last updated: 04/07/2022
-
List item
Human medicine European public assessment report (EPAR): Uptravi (updated)
Selexipag, Hypertension, Pulmonary
Date of authorisation: 12/05/2016, Revision: 13, Authorised, Last updated: 01/07/2022 -
List item
Human medicine European public assessment report (EPAR): Avastin (updated)
bevacizumab, Carcinoma, Non-Small-Cell Lung; Breast Neoplasms; Ovarian Neoplasms; Colorectal Neoplasms; Carcinoma, Renal Cell
Date of authorisation: 12/01/2005, Revision: 60, Authorised, Last updated: 01/07/2022 -
List item
Human medicine European public assessment report (EPAR): Pregabalin Sandoz (updated)
pregabalin, Anxiety Disorders; Neuralgia; Epilepsy
Date of authorisation: 19/06/2015,, Revision: 13, Authorised, Last updated: 01/07/2022
-
List item
Human medicine European public assessment report (EPAR): Cuprymina (updated)
copper (64Cu) chloride, Radionuclide Imaging
Date of authorisation: 23/08/2012, Revision: 8, Authorised, Last updated: 01/07/2022 -
List item
Human medicine European public assessment report (EPAR): Levetiracetam Actavis (updated)
levetiracetam, Epilepsy
Date of authorisation: 03/10/2011,, Revision: 18, Authorised, Last updated: 01/07/2022
-
List item
Human medicine European public assessment report (EPAR): Pregabalin Sandoz GmbH (updated)
pregabalin, Anxiety Disorders; Epilepsy
Date of authorisation: 19/06/2015,, Revision: 12, Authorised, Last updated: 01/07/2022
-
List item
Human medicine European public assessment report (EPAR): Zostavax (updated)
varicella-zoster virus (live, attenuated), Herpes Zoster; Immunization
Date of authorisation: 19/05/2006, Revision: 33, Authorised, Last updated: 01/07/2022 -
List item
Human medicine European public assessment report (EPAR): COVID-19 Vaccine (inactivated, adjuvanted) Valneva (updated)
SARS-CoV-2 virus (inactivated) Wuhan strain hCoV-19 / Italy / INMI1-isl / 2020, COVID-19 virus infection
Date of authorisation: 24/06/2022,, Authorised, Last updated: 01/07/2022
-
List item
Human medicine European public assessment report (EPAR): Ristfor (updated)
sitagliptin, metformin hydrochloride, Diabetes Mellitus, Type 2
Date of authorisation: 15/03/2010, Revision: 25, Authorised, Last updated: 01/07/2022 -
List item
Human medicine European public assessment report (EPAR): Rydapt (updated)
Midostaurin, Leukemia, Myeloid, Acute; Mastocytosis
Date of authorisation: 18/09/2017,, Revision: 8, Authorised, Last updated: 01/07/2022
-
List item
Human medicine European public assessment report (EPAR): Clopidogrel Taw Pharma (previously Clopidogrel Mylan) (updated)
clopidogrel hydrochloride, Peripheral Vascular Diseases; Stroke; Myocardial Infarction; Acute Coronary Syndrome
Date of authorisation: 21/09/2009,, Revision: 20, Authorised, Last updated: 01/07/2022
-
List item
Human medicine European public assessment report (EPAR): Thalidomide BMS (previously Thalidomide Celgene) (updated)
Thalidomide, Multiple Myeloma
Date of authorisation: 16/04/2008, Revision: 30, Authorised, Last updated: 01/07/2022 -
List item
Human medicine European public assessment report (EPAR): Levetiracetam Actavis Group (updated)
levetiracetam, Epilepsy
Date of authorisation: 04/12/2011,, Revision: 16, Authorised, Last updated: 01/07/2022
-
List item
Human medicine European public assessment report (EPAR): Xermelo (updated)
telotristat etiprate, Carcinoid Tumor; Neuroendocrine Tumors
Date of authorisation: 17/09/2017,, Revision: 13, Authorised, Last updated: 01/07/2022
-
List item
Human medicine European public assessment report (EPAR): Ristaben (updated)
sitagliptin, Diabetes Mellitus, Type 2
Date of authorisation: 15/03/2010, Revision: 24, Authorised, Last updated: 01/07/2022 -
List item
Human medicine European public assessment report (EPAR): Samsca (updated)
Tolvaptan, Inappropriate ADH Syndrome
Date of authorisation: 02/08/2009, Revision: 15, Authorised, Last updated: 01/07/2022